Scandion Oncology provides a clear path to market for SCO-101 at today’s Capital Markets Day

Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced it will provide novel information on its lead candidate drug SCO-101 and a focused clinical strategy with a clear path to registration at today’s Capital Markets Day. The company will also communicate about its pipeline, future business opportunities and give an update from part 1 of the CORIST Phase II study.

The release as fetched from its publisher. scandiononcology.com ↗